000			01462 a2200445 4500
005			20250512140333.0
264		0	_c19740506
008			197405s 0 0 eng d
022			_a0003-4886
040			_aNLM _beng _cNLM
100	1		_aPolascik, M
245	0	0	_aRifampicin. _h[electronic resource]
260			_bAnnals of ophthalmology _cAug 1971
300			_a877-82 p. _bdigital
500			_aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article
650	0	4	_aAdenoviridae _xdrug effects
650	0	4	_aAdministration, Oral
650	0	4	_aAnimals
650	0	4	_aBacteria _xdrug effects
650	0	4	_aChemical Phenomena
650	0	4	_aChemistry
650	0	4	_aClinical Trials as Topic
650	0	4	_aConjunctivitis _xdrug therapy
650	0	4	_aDNA-Directed RNA Polymerases
650	0	4	_aDrug Resistance, Microbial
650	0	4	_aDrug Synergism
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEye Diseases _xdrug therapy
650	0	4	_aHaemophilus Infections _xdrug therapy
650	0	4	_aHumans
650	0	4	_aIsoniazid _xtherapeutic use
650	0	4	_aMycobacterium _xdrug effects
650	0	4	_aMycobacterium tuberculosis _xdrug effects
650	0	4	_aRifampin _xadministration & dosage
650	0	4	_aTuberculosis _xdrug therapy
650	0	4	_aVaccinia _xdrug therapy
650	0	4	_aVaccinia virus _xdrug effects
700	1		_aGolden, B
773	0		_tAnnals of ophthalmology _gvol. 3 _gno. 8 _gp. 877-82
999			_c5008417 _d5008417